Daiwa Securities Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Daiwa Securities Group’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-30	Closed	–	–	1408
2023 Q3	$0	Hold	30	–	–	﹤0.01%	1346
2023 Q2	$1K	Hold	30	–	–	﹤0.01%	1310
2023 Q1	$1K	Hold	30	–	–	﹤0.01%	1293
2022 Q4	$1K	Hold	30	–	–	﹤0.01%	1300
2022 Q3	$1K	Hold	30	–	–	﹤0.01%	1322
2022 Q2	$1K	Hold	30	–	–	﹤0.01%	1332
2022 Q1	$1K	Hold	30	–	–	﹤0.01%	1353
2021 Q4	$2K	Hold	30	–	–	﹤0.01%	1311
2021 Q3	$2K	Hold	30	–	–	﹤0.01%	1252
2021 Q2	$1K	Hold	30	–	–	﹤0.01%	1228
2021 Q1	$1K	Hold	30	–	–	﹤0.01%	1239
2020 Q4	$1K	Sell	30 -52	-63%	-$2.43K	﹤0.01%	1220
2020 Q3	$3K	Hold	82	–	–	﹤0.01%	1125
2020 Q2	$4K	Hold	82	–	–	﹤0.01%	1131
2020 Q1	$4K	Hold	82	–	–	﹤0.01%	1127
2019 Q4	$5K	Hold	82	–	–	﹤0.01%	1112
2019 Q3	$5K	Hold	82	–	–	﹤0.01%	1079
2019 Q2	$5K	Hold	82	–	–	﹤0.01%	1110
2019 Q1	$4K	Hold	82	–	–	﹤0.01%	1099
2018 Q4	$3K	Hold	82	–	–	﹤0.01%	1097
2018 Q3	$6K	Hold	82	–	–	﹤0.01%	1077
2018 Q2	$6K	Hold	82	–	–	﹤0.01%	1089
2018 Q1	$4K	Buy	+82	New	+$4.77K	﹤0.01%	1093

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Daiwa Securities Group's EGRX Position: Q4 2023 in Review

Daiwa Securities Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2023, closing a stake of 30 shares.

Daiwa Securities Group first reported a position in EGRX in Q1 2018 and held it in 23 quarters. The position peaked at $6K in Q3 2018. 104 funds tracked by Wall St. Rank hold EGRX as of Q4 2023.

Daiwa Securities Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
Daiwa Securities Group sold 30 Eagle Pharmaceuticals, Inc. shares in Q4 2023.
Daiwa Securities Group first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2018 and held it in 23 quarters.
Daiwa Securities Group's Eagle Pharmaceuticals, Inc. position peaked at $6K in Q3 2018.
104 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2023.

Based on Daiwa Securities Group's 13F filing for Q4 2023, filed 31 Jan 2024.